The Genomeweb business news section presents a snapshot of recent developments across the genomics and life science markets, emphasizing financial shifts, legal rulings, partnerships, and technology trends. The page highlights that private financing for life science tools and diagnostics firms fell 20 percent in H2 2025, with the tools segment particularly affected as tariffs, high interest rates, and uncertainty around federal research funding created a challenging environment. In parallel, a string of corporate moves, from reverse stock splits to share repurchase plans, illustrate how genomics and diagnostics companies are adjusting capital structures and investor strategies amid tighter conditions.
Several individual company actions stand out in the business news feed. Co-Diagnostics plans to execute a 1-for-30 reverse stock split that is intended to enable the molecular diagnostics firm to regain compliance with the $1 bid price requirement for continued listing on the Nasdaq. Qiagen detailed a $500M synthetic share repurchase plan, signaling confidence in its valuation while returning capital to shareholders. Bruker agreed to pay AbCellera $36M plus royalties to settle an intellectual property dispute, while CareDx proposed a settlement deal in a shareholder class action lawsuit, underscoring how legal and governance issues are intersecting with business strategy.
The roundup also captures an active landscape of partnerships, product initiatives, and regulatory interactions. KDA Group and AstraZeneca Canada announced a collaboration to support next-generation sequencing diagnostic testing for metastatic breast cancer patients at Hôpital du Saint-Sacrement in Quebec City. Parse Biosciences and Codebreaker Labs partnered to map the effects of genetic variants on single cells, while Wasatch BioLabs and Agilent inked a comarketing deal for a targeted nanopore methylation sequencing service. Applied BioCode submitted a new sample preparation claim to the US Food and Drug Administration to expand use of its respiratory panel, and Singlera Genomics signed an EU distribution deal with Pure Medical for cell-free DNA assays. At the same time, concerns about security and policy are evident, as highlighted by coverage of the Biosecure Act provisions becoming law after Senate passage of the annual national defense bill, BGI Group’s criticism that the National Defense Authorization Act stifles competition and favors US firms, and a premium article warning that Artificial Intelligence protein design tools pose biosecurity risks for DNA makers. This context frames growing interest in genomics data offerings for pharma, the impact of the US Food and Drug Administration rule on laboratory-developed tests, and a notable ruling by the EU Unified Patent Court in favor of Myriad Genetics in a breast cancer intellectual property dispute.
